Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 5 - October 2018
  3. 3rd meeting of the federation of neurogastroenterology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 5 - October 2018
  3. 3rd meeting of the federation of neurogastroenterology
Gastroenterology

3rd meeting of the federation of neurogastroenterology

IBD

Congress review

By Dr. Jari Punkkinen
Head of Endoscopy Unit, Porvoo Hospital, Department of Medicine, Finland

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Image1_Article5_Microbiota_NL-5_FR

About this article

Created 26 August 2021
Updated 27 September 2021

Selected experts about Irritable Bowel Syndrome and Gut Microbiota.

Gut microbiota dysbiosis in IBS

Microbiota dysbiosis and its relation to irritable bowel syndrome (IBS) was discussed during various sessions of the conference. In particular, Pr. Magnus Simrén and Pr. Uday Ghoshal highlighted some features related to microbiota composition of IBS patients. Based on several studies, IBS patients have been shown to have a low microbial richness compared to healthy individuals, and Methanobacteriales may be undetected and methane production low in such patients [1].

Furthermore, a subset of IBS patients present dysbiosis with increased Firmicutes and Bacteroides enterotypes compared to healthy individuals with enriched Clostridiales and Prevotella enterotypes. However, an important question is not only which bacteria are associated with IBS but what they do in the gut and how they are involved in mechanisms of visceral hypersensitivity, neuro-motor dysfunction, increased permeability, and low-grade inflammation. Small intestine bacterial overgrowth (SIBO) may be the cause of IBS in some patients and a current challenge is to improve screening for these patients as upper gut aspirate culture is difficult to perform and not always available. The glucose hydrogen breath test may be used to identify such patients, and this would appear to be more accurate than the lactulose hydrogen breath test [2].

Gut microbiota modulation in IBS

Can the gut microbiome be changed for therapeutic purposes and could it relieve IBS symptoms? Options to modulate gut microbiota include antibiotics, probiotics, synbiotics, altering gut motility, dietary manipulation, fecal transplantation, and use of bacteriophages. These therapies were discussed in the presentations of Pr. Uday Ghoshal and Pr. Giovanni Barbara. A role for antibiotics is most apparent in IBS-patients with SIBO. Both norfloxacin and rifaximin are significantly more effective in reducing IBS symptoms in SIBO- positive than SIBO-negative patients.

In IBS patients without constipation, according to Target 1 and 2 studies, rifaximin relieves global IBS-symptoms, and bloating. Target 3 and further studies have shown that rifaximin can be used repeatedly in relapsing IBS-D without loss of effect or appearance of bacterial resistance [3, 4]. Moreover, rifaximin transiently reduces bacterial counts in the feces but it also seems to have an eubiotic effect increasing Lactobacillaceae abundance.

The low FODMAP diet seems to reduce symptoms in some IBS patients but it also results in lower Bifidobacterium counts in the feces. In IBS patients responding to a low FODMAP diet the dysbiosis index increases, thus responsiveness to the diet may be predicted by faecal bacterial profiles. The efficacy of fecal microbial transplantation in IBS remains controversial as this was demonstrated in only one of the two large randomized controlled studies [5, 6]. As stated by Pr. Giovanni Barbara, the American College of Gastroenterology, based on a meta-analysis of 53 randomized controlled trials, concluded that probiotics reduce global IBS symptoms as well as bloating and flatulence [7]. To be consolidated, this recommendation should be founded on new, high-quality data.

However, not all probiotics are similar. Bifidobacterium infantis was shown by prof. Eamonn Quigley to relieve abdominal pain, bloating, and bowel function and improve quality of life in patients with all IBS-subtypes, and this appears to have anti-inflammatory and immunomodulating properties reducing CRP and TNFα in conditions like psoriasis, chronic fatigue syndrome, and ulcerative colitis. Furthermore, preliminary results suggest that in combination with Bifidobacterium longum it might also relieve depression in patients with IBS.

The microbiome and gut-brain axis

Based on preclinical studies, products of gut bacteria have been shown to change brain responses to stimuli, however the challenge is to translate these studies to clinical relevance. Huiying Wang showed in her recent study that Bifidobacterium longum strain modulates brain activity during social stress (associated with a cyberball game) in healthy volunteers based on evaluation using magnetoencephalography and QOL questionnaires. Besides an effect on neural oscillations, the strain also enhances a feeling of vitality and reduces mental fatigue compared to placebo over a four-week follow-up period. Pr. Paul Enck described the relationship between stress or anxiety and IBS as two-way as the symptoms can be both the cause and result of IBS. Based on a study of patients with IBS, Bifidobacterium longum was shown to correlate with a decrease in depression and anxiety scores, but at onset, these scores were insufficiently high to establish a diagnosis of depression or anxiety [8]. Thus, it is more appropriate to state that this probiotic affects mood rather than depression or anxiety. Similar to Bifidobacterium longum, rifaximin has also been shown to modulate brain activity and increase relaxation and reduce anxiety during social stress based on a double blindedrandomized trial of healthy volunteers evaluated by magnetoencephalography [9].

Sources

1 Tap J, Derrien M, Törnblom H et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152: 111-23.

2 Ghoshal UC, Sukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017; 11: 196-208.

3 Lembo A, Pimentel M, Rao SS et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel. Gastroenterology 2016;151;1113-21

4 Pimentel M, Cash BD, Lembo A et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci 2017;62:2455-2463

5 Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018; 3: 17-24.

6 Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115.

7 Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology Monograph on management of irritable bowel syndrome. Am J Gastroenterol 2018; 113: 1-18.

8 Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 2017; 153: 448-59.

9 Wang H, Braun C, Enck P. Effects of rifaximin on central responses to social stress – a pilot experiment. Neurotherapeutics 2018; 15; 807-8.

Tags
Gastroenterology Gut-brain axis ENSM

en_view en_sources

    Focus
    Microbiota 5 - October 2018
    • Overview
      • The gut microbiome and neurodegeneration
    • Commented articles
      • The food additive trehalose increases the virulence of epidemic clostridium difficile
      • Gut microbiota profiles in untreated children with attention deficit hyperactivity disorder
    • Congress review
      • 51st annual Meeting ESPGHAN
      • 3rd meeting of the federation of neurogastroenterology
    • Press review
      • Microbiota and non-antibiotic drugs interactions: friends or foes?
      • Microbiota and cystic fibrosis
    Created 26 August 2021
    Updated 27 September 2021

    About this article

    To know more about this topic.

    Main topic

    IBD

    Content type

    Congress review
    51st annual Meeting ESPGHAN
    Microbiota and non-antibiotic drugs interactions: friends or foes?
    Focus

    Microbiota 5 - October 2018

    Overview

    The gut microbiome and neurodegeneration

    Commented articles

    The food additive trehalose increases the virulence of epidemic clostridium difficile Gut microbiota profiles in untreated children with attention deficit hyperactivity disorder

    Congress review

    51st annual Meeting ESPGHAN 3rd meeting of the federation of neurogastroenterology

    Press review

    Microbiota and non-antibiotic drugs interactions: friends or foes? Microbiota and cystic fibrosis
    Gastroenterology
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo